Literature DB >> 23165663

Screening for HIV in pregnant women: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation.

Roger Chou1, Amy G Cantor, Bernadette Zakher, Christina Bougatsos.   

Abstract

BACKGROUND: A 2005 U.S. Preventive Services Task Force (USPSTF) review found good evidence that prenatal HIV screening is accurate and can lead to interventions that reduce the risk for mother-to-child transmission.
PURPOSE: To update the 2005 USPSTF review, focusing on previously identified research gaps and new evidence on treatments. DATA SOURCES: MEDLINE (2004 to June 2012) and the Cochrane Library (2005 to the second quarter of 2012). STUDY SELECTION: Randomized trials and cohort studies of pregnant women on risk for mother-to-child transmission or harms associated with prenatal HIV screening or antiretroviral therapy during pregnancy. DATA EXTRACTION: 2 reviewers abstracted and confirmed study details and quality by using predefined criteria. DATA SYNTHESIS: No studies directly evaluated effects of prenatal HIV screening on risk for mother-to-child transmission or maternal or infant clinical outcomes. One fair-quality, large cohort study (HIV prevalence, 0.7%) found that rapid testing during labor was associated with a positive predictive value of 90%. New cohort studies of nonbreastfeeding women in the United States and Europe confirm that full-course combination antiretroviral therapy reduces rates of mother-to-child transmission (<1% to 2.4% vs. 9% to 22% with no antiretroviral therapy). New cohort studies found antiretroviral therapy during pregnancy to be associated with increased risk for preterm delivery (<37 weeks' gestation); there were no clear associations with low birthweight, congenital abnormalities, or infant neurodevelopment. Evidence on long-term maternal harms after short-term antiretroviral therapy exposure during pregnancy remains sparse. LIMITATIONS: Only English-language articles were included. Studies conducted in resource-poor settings may be of limited applicability to screening in the United States.
CONCLUSION: Antiretroviral therapy in combination with avoidance of breastfeeding and elective cesarean section in women with viremia reduces risk for mother-to-child transmission. Use of certain antiretroviral therapy regimens during pregnancy may increase risk for preterm delivery. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23165663     DOI: 10.7326/0003-4819-157-10-201211200-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  6 in total

Review 1.  Women's willingness to be tested for human immunodeficiency virus during pregnancy: A review.

Authors:  Merav Ben-Natan; Yelena Hazanov
Journal:  World J Virol       Date:  2015-08-12

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

3.  Development of an electronic medical record-based algorithm to identify patients with unknown HIV status.

Authors:  Uriel R Felsen; Eran Y Bellin; Chinazo O Cunningham; Barry S Zingman
Journal:  AIDS Care       Date:  2014-04-30

4.  Sustainability of Statewide Rapid HIV Testing in Labor and Delivery.

Authors:  Lynn M Yee; Emily S Miller; Anne Statton; Laurie D Ayala; Sarah Deardorff Carter; Ann Borders; Amy E Wong; Yolanda Olszewski; Mardge H Cohen; Patricia M Garcia
Journal:  AIDS Behav       Date:  2018-02

5.  Recommendations for lab-based screening tests for adult women.

Authors:  Shahram Shahangian
Journal:  Adv Adm Lab       Date:  2014-08-04

Review 6.  Effect of rapid HIV testing on HIV incidence and services in populations at high risk for HIV exposure: an equity-focused systematic review.

Authors:  Kevin Pottie; Olanrewaju Medu; Vivian Welch; Govinda P Dahal; Mark Tyndall; Tamara Rader; George Wells
Journal:  BMJ Open       Date:  2014-12-15       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.